8-K: Humacyte Q3 2025: Symvess Sales Surge, Pipeline Advances

Humacyte reports substantial Q3 2025 revenue growth driven by Symvess sales, positive clinical data for ATEV in dialysis, and pipeline progress for CTEV.

Summary

• Total revenues for the third quarter ended September 30, 2025, were $753,000, with $703,000 from U.S. sales of Symvess.
• Symvess sales increased significantly from $100,000 in Q2 2025 to $703,000 in Q3 2025.
• The company achieved 25 Value Analysis Committee (VAC) approvals, making Symvess eligible for purchase in 92 civilian hospitals, with 45 additional VAC committees under review.
• Positive two-year results from the V007 Phase 3 trial for the ATEV in dialysis patients were presented, showing superior duration of use over 24 months compared to autogenous fistula in high-need subgroups.
• Humacyte plans to submit a supplemental Biologics License Application (BLA) for the ATEV in dialysis in the second half of 2026.
• Preclinical study results for the Coronary Tissue Engineered Vessel (CTEV) in non-human primates were positive, supporting plans for a first-in-human study in CABG in 2026.
• An Investigational New Drug (IND) application for the CABG indication has been submitted to the FDA.
• Net loss for Q3 2025 significantly decreased to $17.5 million from $39.2 million in Q3 2024, primarily due to a non-cash remeasurement of a contingent earnout liability and reduced operating expenses.
• Cash, cash equivalents, and restricted cash stood at $19.8 million as of September 30, 2025, with an additional $56.5 million in net proceeds from a stock and warrant sale completed subsequent to the quarter end.

Sentiment

Score: 8

Explanation: The filing indicates strong commercial traction for Symvess, significant progress in key clinical trials (ATEV dialysis, CTEV CABG), and a substantial reduction in net loss. The recent capital raise also addresses immediate liquidity concerns. While operating cash burn remains, the overall trajectory and pipeline advancements are highly positive.

Positives

• Substantial increase in Symvess sales to $703,000 in Q3 2025, up from $100,000 in Q2 2025.
• Expansion of Symvess market access with 25 VAC approvals covering 92 civilian hospitals and 45 additional VAC committees under review.
• Positive clinical outcomes for Symvess in vascular trauma, including high patency, 100% limb salvage, and zero conduit infection rates in published studies.
• Superior duration of use observed for ATEV in dialysis patients over 24 months compared to autogenous fistula in high-need subgroups from the V007 Phase 3 trial.
• Successful preclinical results for CTEV in non-human primates, supporting advancement to first-in-human studies for CABG.
• Submission of an IND to the FDA for the CABG indication, marking progress in pipeline development.
• Expansion of intellectual property with a new U.S. patent for bioengineered esophagus, extending protection into 2041.
• Significant reduction in net loss for Q3 2025 to $17.5 million from $39.2 million in Q3 2024, driven by non-cash adjustments and operating expense reductions.
• Completion of a capital raise subsequent to quarter-end, generating approximately $56.5 million in net proceeds, strengthening the cash position.

Negatives

• Total net cash used in operating activities increased to $78.9 million for the first nine months of 2025, compared to $71.5 million for the same period in 2024, primarily due to inventory buildup for Symvess launch.
• Selling, general and administrative expenses increased to $7.6 million for Q3 2025 and $23.6 million for 9M 2025, primarily due to the U.S. commercial launch of Symvess.

Risks

• Ability to commercialize Symvess and, if approved, product candidates successfully and on anticipated timelines.
• Degree of market acceptance and availability of third-party coverage and reimbursement for Symvess and product candidates.
• Ability to manufacture Symvess and product candidates in sufficient quantities to satisfy clinical trial and commercial needs.
• Uncertainty regarding the anticipated benefits of ATEVs and CTEVs relative to existing alternatives.
• Ability to execute product development, process development, and preclinical development efforts successfully and on anticipated timelines.
• Ability to file applications for, and obtain marketing approvals from, the FDA and other regulatory authorities for ATEVs, CTEVs, and product candidates.
• Ability to design, initiate, and successfully complete clinical trials and other studies for product candidates.
• Uncertainty regarding the anticipated characteristics and performance of ATEVs and CTEVs.
• Ability to use the proprietary scientific technology platform to build a pipeline of additional product candidates.
• Implementation of the business model and strategic plans for the business.
• Ability to execute and achieve the expected benefits of cost-saving measures and whether efforts will result in further actions or additional asset impairment charges.
• Changes in applicable laws or regulations.
• Adverse effects from other economic, business, and/or competitive factors.

Future Outlook

Humacyte plans to continue the U.S. commercial launch of Symvess, aiming for further increases in sales and VAC approvals. The company intends to submit a supplemental Biologics License Application (BLA) for the ATEV in dialysis in the second half of 2026, contingent on interim results from the V012 Phase 3 trial. Additionally, Humacyte plans to advance its Coronary Tissue Engineered Vessel (CTEV) into a first-in-human study for coronary artery bypass grafting (CABG) in 2026, following the submission of an Investigational New Drug (IND) application to the FDA.

Management Comments

• "During the third quarter of 2025 we continued to execute on our U.S. commercial launch of Symvess with sales increasing substantially, totaling $703,000 for third quarter compared to $100,000 in second quarter."
• "This significant ramp-up is due to an increased number of individual hospital and healthcare system Value Analysis Committee (VAC) approvals, our recent inclusion in the U.S. Defense Logistics Agencys Electronic Catalog (ECAT), and the tireless work of our commercial and medical teams in educating the vascular surgery community about the benefits of Symvess."
• "The launch of Symvess in the vascular trauma indication is just the first of the many planned products emerging from our proprietary bioengineering platform, and the advancement of our broader pipeline was supported by multiple events during the quarter."
• "The acellular tissue engineered vessel (ATEV) is moving closer to our planned supplemental Biologics License Application (BLA) filing in dialysis access."
• "For coronary artery bypass grafting (CABG), we published positive results of a preclinical study evaluating our coronary tissue engineered vessel (CTEV) in non-human primates. These results support our plans to advance the CTEV into a human study in CABG in 2026."
• "If successful, the CTEV would be the first novel conduit tested in CABG in the US in decades."

Industry Context

Humacyte operates in the rapidly evolving biotechnology and regenerative medicine sector, focusing on bioengineered human tissues. The successful commercial launch of Symvess for vascular trauma and the advanced pipeline for dialysis access and CABG position the company as a potential innovator in addressing significant unmet medical needs in vascular surgery. The emphasis on universally implantable, off-the-shelf tissues could disrupt traditional approaches that rely on autologous grafts or synthetic materials, offering advantages in availability and potentially reducing complications. The positive clinical data for ATEV in dialysis and the preclinical success of CTEV suggest a strong competitive edge in areas where current solutions have limitations, aligning with broader industry trends towards advanced biomaterials and personalized medicine.

Comparison to Industry Standards

• Symvess demonstrated similar short-term outcomes for patency, limb salvage, and infection when compared to autologous vein in the treatment of extremity arterial trauma, as published in Trauma Surgery & Acute Care Open Journal.
• The ATEV in dialysis showed superior duration of use over 24 months compared to autogenous fistula in high-need subgroups, which historically have poor outcomes with arteriovenous (AV) fistula procedures, potentially reducing reliance on catheters.
• The Coronary Tissue Engineered Vessel (CTEV), if successful in human studies, would be the first novel conduit tested in CABG in the U.S. in decades, highlighting its potential to significantly advance the standard of care in coronary artery bypass grafting.

Stakeholder Impact

• **Shareholders**: Positive impact due to strong sales growth, pipeline advancements, reduced net loss, and a successful capital raise, which could lead to increased shareholder value. Dilution from the recent stock and warrant sale is a consideration.
• **Patients**: Potential for improved treatment options with Symvess for vascular trauma, ATEV for dialysis access (superior duration of use), and future CTEV for CABG, offering better outcomes and reduced complications.
• **Healthcare Providers/Hospitals**: Increased access to Symvess through VAC approvals and inclusion in the U.S. Defense Logistics Agency's ECAT, providing novel solutions for vascular injuries.
• **Employees**: Continued growth and pipeline development suggest job stability and potential for expansion within the company.
• **Creditors**: Improved financial health and a strengthened cash position from the capital raise reduce immediate credit risk.

Next Steps

• Continue U.S. commercial launch of Symvess, focusing on increasing VAC approvals and hospital orders.
• Advance the ATEV in dialysis towards a planned supplemental BLA filing in the second half of 2026, contingent on interim V012 Phase 3 trial results.
• Progress the CTEV into a first-in-human study for CABG in 2026, following the submitted IND application.
• Continue development of other pipeline products, leveraging expanded intellectual property in bioengineered tissues.

Key Dates

Recommendation

The filing demonstrates significant positive momentum across multiple fronts. Symvess sales are ramping up substantially, indicating strong market acceptance for an approved product. The positive two-year Phase 3 data for ATEV in dialysis and the progression of CTEV into human studies for CABG represent major advancements in a robust pipeline, addressing large unmet medical needs. The dramatic reduction in net loss, coupled with a successful $56.5 million capital raise post-quarter, significantly de-risks the company's financial position and provides runway for continued development and commercialization. These factors collectively point to a strong growth trajectory and potential for significant future value creation, making it a compelling 'strong buy' for investors seeking exposure to innovative biotechnology with commercial traction and a deep pipeline.

Keywords

Humacyte, HUMA, Symvess, ATEV, CTEV, bioengineered tissues, vascular trauma, dialysis access, coronary artery bypass graft, CABG, biotechnology, medical devices, regenerative medicine, SEC filing, financial results, Q3 2025, clinical trials, FDA, BLA, IND, intellectual property